HR+/HER2- Early Breast Cancer Clinical Trials in Xi'an, Shaanxi

A Study on the Use of Fluzoparib Combined With Chemotherapy for Neoadjuvant Treatment of HRD-positive, HR+/HER2- Breast Cancer